Aurelius Omlin

Aurelius Omlin

Affiliation: 
Kantonsspital St. Gallen, Medical Oncology
Country: 
Switzerland
City: 
St. Gallen
Education
  • 1983 – 1997: School education and high school, graduation 1997
  • 1997 – 2003: Medical School, University of Berne
Postgraduate Training
  • 12.2003 – 12.2004: Department of Radiation Oncology, University Hospital Berne (Prof. Greiner)
  • 01.2005 – 06.2006: Internal Medicine, Regionalspital Thun (U. Stoller, MD)
  • 07.2006 – 09.2010: Department of Oncology/Hematology, Cantonal Hospital St.Gallen (Prof. Th. Cerny).
  • 10.2010 – 12.2011: Senior clinical research fellow, Drug Development Unit (DDU) of the Royal Marsden NHS Foundation Trust, Sutton (Prof. S. Kaye and Prof. J. de Bono)
  • 01.2012 – 06.2013: Senior clinical research fellow, Prostate Targeted Therapies Group (PTTG), Royal Marsden NHS Foundation Trust (Prof. J. de Bono)
  • From 07.2013: Consultant Department of Oncology/Haematology, Cantonal Hospital St.Gallen (Prof. Th. Cerny)
Credentials
  • 2003: Swiss Physician Diploma, University of Berne, (Summa cum laude)
  • 2003: Doctoral degree: MD Thesis: “The Swiss Study Group for Complementary and Alternative Methods in Cancer 1982-2002 “Thesis advisor: Prof. U. Boschung, MD, Institut of Medical History, University of Berne
  • 2004: University of Berne Research Reportage Award
  • 2010: ESMO-ECCO Masterclass in Clincial Oncology
  • 2010: ECCO - AACR - EORTC - ESMO Workshop on 'Methods in Clinical Cancer Research'
  • 07.2010: GMC Registration: Full Registration, GMC Nr: 7083620 until July 2013
  • 11.2010: GCP TRAINING COURSE
  • 11.2012: GCP TRAINING COURSE
  • 09.2012: ESMO Merit Award (ESMO Vienna 2012)
  • 11.2013: Medical Oncology Specialist Examination/Registration (FMH)
  • 05.2013: ASCO Merit Award (Chicago 2013 and oral presentation)
Grants
  • 2010-2012: Swiss Cancer League Bursary (BIL KLS-02592-02-2010): CHF 136’000
  • 2012: Adolf and Lotte Hotz-Sprenger Foundation (CHF 20’000) (Carboplatin trial)
  • 2013: Co-Applicant for “RE-AKT A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration-Resistant Prostate Cancer” (CRUK and AstraZeneca: £ 3.500.000)
  • 2013 and 2014: Pilottestung eines Untersuchungsinstrumentes zur Messung der Lebensqualität bei CRPC Patienten (OSKK CHF 29’000 + 27’904).
  • 2013: „Lebensqualität bei Patienten mit CRPC“ (Lotex-Stiftung CHF 20’000)
  • 2014: Anschubfinanzierung (Pilot Study of Carboplatin in patients with PTEN loss; CHF 48’7000.-)
  • 2014: Swiss Bridge Foundation: CHF 300’000 for Pilot study of Carboplatin in patients with PTEN loss.
  • 2014: IIT: Abiraterone re-challenge, a phase II pilot biomarker study (CHF 795’000)
Teaching
  • 2007 – 2010: Full-day teachings for advanced nurses in palliative care anorexia/cachexia, palliative emergencies, palliative sedation
  • From 2013: Clinical Skills Tutoring (CST, 3rd year medical students, University of Berne)
  • From 2013: Various teaching commitments (Nachdiplom-Studium Pflege, Onkologiepflege Schweiz, interprofessionelle Weiterbildung Psycho-Onkologie)
Memberships
  • SAKK (Schweizerische Arbeitsgruppe für Klinische Krebsforschung)
  • ESMO (European Society of Medical Oncology)
  • ASCO (American Society of Clinical Oncology)
  • FMH (Swiss Medical Association)